CURIS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
CURIS, INC. (CRIS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $312.08 per share as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-14
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $312.08.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $15.67.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $16.59.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $17.19.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $312.08 10-Q · filed 2026-08-14 |
| 2026-03-31 | $15.67 10-Q · filed 2026-05-13 |
| 2025-12-31 | $16.59 10-K · filed 2026-03-24 |
| 2025-09-30 | $17.19 10-Q · filed 2025-11-06 |
| 2025-06-30 | $17.30 10-Q · filed 2025-08-05 |
| 2025-03-31 | $24.82 10-Q · filed 2025-05-06 |
| 2024-12-31 | $33.44 10-K · filed 2025-03-31 |
| 2024-09-30 | $33.44 10-Q · filed 2024-11-14 |
| 2024-06-30 | $35.23 10-Q · filed 2024-08-01 |
| 2024-03-31 | $38.07 10-Q · filed 2024-05-07 |
| 2023-09-30 | $48.16 10-Q · filed 2023-11-02 |
| 2023-06-30 | $2.44 10-Q · filed 2023-08-03 |
| 2023-03-31 | $2.48 10-Q · filed 2023-05-04 |
| 2022-09-30 | $3.61 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.46 10-Q · filed 2022-08-04 |
| 2022-03-31 | $3.49 10-Q · filed 2022-05-05 |
| 2021-09-30 | $3.73 10-Q · filed 2021-11-09 |
| 2021-06-30 | $3.63 10-Q · filed 2021-08-03 |
| 2021-03-31 | $3.54 10-Q · filed 2021-05-12 |
| 2020-09-30 | $2.81 10-Q · filed 2020-11-10 |
| 2020-06-30 | $2.83 10-Q · filed 2020-08-04 |
| 2020-03-31 | $2.86 10-Q · filed 2020-05-12 |
| 2019-09-30 | $3.75 10-Q · filed 2019-11-05 |
| 2019-06-30 | $4.21 10-Q · filed 2019-08-09 |
| 2019-03-31 | $5.82 10-Q · filed 2019-05-14 |
| 2018-09-30 | $8.43 10-Q · filed 2018-11-01 |
| 2018-06-30 | $9.74 10-Q · filed 2018-08-02 |
| 2018-03-31 | $2.25 10-Q · filed 2018-05-03 |
| 2017-09-30 | $2.40 10-Q · filed 2017-11-07 |
| 2017-06-30 | $2.39 10-Q · filed 2017-08-03 |
| 2017-03-31 | $2.38 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |